c-Src expression is predictive of poor prognosis in breast cancer patients with bone metastasis, but not in patients with visceral metastasis.
c-Src expression is critical for breast cancer progression and it is particularly important for bone metastasis. In this study, we aimed to evaluate the effect of c-Src on prognosis in metastatic breast cancer patients, and to conduct subgroup analysis to explore the role of c-Src in bone metastasis and visceral metastasis respectively. We analyzed a total of 102 paraffin-embedded primary tumor tissue sections from metastatic breast cancer patients using immunohistochemical staining for c-Src, including 61 patients with bone metastases. Clinical data were collected retrospectively. We utilized survival analysis and the Cox proportional hazards model to explore the prognostic value of c-Src expression in metastatic breast cancer. The c-Src expression rate was 54.9% in the 102 metastatic breast cancer patients. Patients who exhibited c-Src expression demonstrated poor progression-free survival (PFS) (p = 0.044) and disease-specific survival (DSS) (p = 0.017). Subgroup analysis demonstrated that c-Src positive patients exhibited significantly worse bone metastasis-free survival (p = 0.027) and DSS (p = 0.024), whereas in patients with non-bone metastasis no significant difference was observed in PFS (p = 0.819) and DSS (p = 0.381). Multivariate analysis demonstrated that c-Src expression was an independent predictor of DSS for patients with bone metastasis. Our findings demonstrate that c-Src expression is a potential independent predictor of poor prognosis in breast cancer patients with bone metastasis.
Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.
Lingyun
L
Zhang
Yuee
Y
Teng
Ye
Y
Zhang
Jing
J
Liu
Ling
L
Xu
Jinglei
J
Qu
Kezuo
K
Hou
Xianghong
X
Yang
Yunpeng
Y
Liu
Xiujuan
X
Qu
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001859:Bone Neoplasms / Q000201:enzymology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology*; D000081247:CSK Tyrosine-Protein Kinase; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis*; D012189:Retrospective Studies; D016019:Survival Analysis; D019061:src-Family Kinases
D014408:Biomarkers, Tumor; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D019061:src-Family Kinases; C000631346:CSK protein, human